Background: The incidence of infection associated with transrectal prostate biopsy has been increasing largely due to fluoroquinolone resistance (FQR). Purpose: To identify the antibiotic prescribing patterns employed when men seek medical professionals due to infectious complications of prostate biopsy, and employ a quality improvement initiative to improve antibiotic selection. Methods: A retrospective review determined the percentage of patients who presented to the emergency department (ED) after TRUS biopsy, and whether they were given appropriate antibiotic therapy. Prospective quality improvement was initiated by obtaining cultures via rectal swab at the time of transrectal biopsy in order to allow culture results and fluoroquinolone sensitivities to be available in the electronic medical record. The provider to guide antibiotic selection if the patient returned with infection symptoms could utilize the data. Findings: From 10/2009 to 6/2014, 0.5% (9/1724) of patients who underwent TRUS prostate biopsy returned to the ED with infection. Seven patients had complete data and 4 (0.57%) were given appropriate initial antibiotic treatment. To improve antibiotic selection, the 119 men who underwent rectal swab culture prior to biopsy 19.3% (23/119) showed FQR on rectal culture. 4% (5/119) were hospitalized with infection, demonstrating a significant increase in infection incidence from retrospective chart review (0.5% to 4%, p = 0.0013). Of these 5 men, 60% (3/5) had FQR on rectal culture. Conclusions: Rectal culture at the time of biopsy may lead to faster recognition of resistant bacteria when presented with prostate biopsy infection.
Introduction
Transrectal ultrasound guided (TRUS) prostate biopsy is a widely used, minimally invasive procedure implemented in the initial patient work-up for prostate cancer [1] . During the procedure, a needle traverses both the anterior wall of the rectum and the prostate, potentially introducing colonic pathogens into the prostate and surrounding tissues. The bacteria found in the rectum at the time have been confirmed in the blood of post prostate biopsy septicemia confirming the bacteria directly come from the rectal flora [2] . Fluoroquinolone (FQ) antibiotics have historically been the standard prophylactic therapy used to prevent infection following biopsy. Though complications associated with this procedure are rare (1% -6%), the incidence of post-biopsy infections has been increasing over the last decade [1] [3] [4] [5] [6] . Additionally, recent studies have demonstrated an increased incidence of FQ resistance in blood and urine cultures of patients presenting with infectious complications after TRUS prostate biopsy [6] [7] [8] [9] . Improvement can be made in the initial treatment of patients presenting with infections after prostate biopsy. Our purpose is to identify the antibiotic prescribing patterns employed when men seek medical professionals due to infectious complications of TRUS prostate biopsy. Due to the high resistance rate of trimethoprim/sulfamethoxazole and ciprofloxacin, these medications may not be appropriate to treat biopsy complications. We then seek to utilize a quality improvement initiative at the Audie L. Murphy Veterans Affairs Hospital (ALMVAH) to provide an alternative approach to guide antibiotic selection.
Methods

Retrospective Review
A retrospective chart review was performed for all TRUS prostate biopsies performed at ALMVAH within the last 5 years (10/2009 to 6/2014). All patients who presented to the Emergency Department (ED) shortly after biopsy were identified for further chart review. The patients who returned to the ED for a potentially biopsy-related infection were identified, and the antibiotics administered in the emergency department were recorded to identify the number of patients treated with FQ versus any other antibiotic therapy. A simple analysis was performed to identify the percentage of patients who presented to the emergency department with a biopsy related infection, and the percentage of those returning patients who were treated in the emergency department with appropriate antibiotic therapy.
Quality Improvement
In order to determine colonization and FQ resistance, we prospectively cultured patients undergoing TRUS biopsy with rectal swab prior to biopsy from July 6th, 
Results
Retrospective Review
Of the 1724 patients who underwent TRUS prostate biopsy at ALMVAH, 0.5% Of the patients given inappropriate antibiotic treatment in the ED, 2 were given trimethoprim-sulfamethoxazole, and one was given ciprofloxacin (Table   1) . 
Quality Improvement
Discussion
Infection associated with TRUS prostate biopsy is an uncommon presentation to most Emergency Departments; however increased from historical 0.5% to nearly 4% in the 6 months of our study (p = 0.0013). Therefore, providers in emergency departments may not be fully aware of the current increase of infections complications from fluoroquinolone resistance E. coli that has caused the majority of infections. Trimethoprim sulfamethoxazole or another fluoroquinolones would not be appropriate antibiotic selections for men presenting with infectious complications from prostate biopsy. Our examination of the antibiotic resistance profiles of the 21 patients that were colonized with fluoroquinolone resistant E. coli ( Figure 2) show a similar resistance profile as published in other studies [11] . Attention is brought to gentamicin because 28% of men in our study were deemed "at risk" for infection and were given this antibiotic to prevent infection. Two specific issues relating to gentamicin are important to discuss including weight based dosing and secondary resistance. First, gentamicin should be dosed by the patient's weight. The American Urologic Association Best Practice Policy Statement on Urologic Surgery Antimicrobial Prophylaxis recommends 5 mg/kg dosing [12] . After discussion with our pharmacy department, they feel that 2 mg/kg dosing was sufficient for prostate biopsy prophylaxis. The vast majority of our patients are over 80 kg, which means at least a dose of 160 mg would be needed for sufficient antimicrobial coverage. Second, 38% of the 21 fluoroquinolone 
Conclusion
Our study shows a very significant rise in prostate biopsy infection. Historically, these infections may not have been treated appropriately due to the rare occurrence and lack of awareness of this infectious problem unique to the specific pa- 
